Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lung Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Tobacco Use Disorder 3Small Cell Lung Carcinoma 3Head and Neck Neoplasms 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Smoking Cessation 2Pancreatic Neoplasms 2Overweight 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Obesity 2Nasopharyngeal Neoplasms 2Mouth Neoplasms 2Liver Neoplasms 2Leukemia, Myeloid, Acute 2Leukemia 2Laryngeal Neoplasms 2Kidney Neoplasms 2Hypopharyngeal Neoplasms 2Esophageal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Advanced Solid Tumor 2Vulvar Neoplasms 1Vaginal Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

Rituximab 193Cyclophosphamide 177fludarabine phosphate 151Peripheral Blood Stem Cell Transplantation 89fludarabine 77Mycophenolic Acid 70Filgrastim 63Whole-Body Irradiation 59Tacrolimus 55Lenalidomide 54Cyclosporine 54ibrutinib 53Bendamustine Hydrochloride 50Busulfan 49Melphalan 45Radiotherapy 42Etoposide 42Alemtuzumab 42Antilymphocyte Serum 40ofatumumab 35obinutuzumab 33Methotrexate 33venetoclax 27Cytarabine 25sargramostim 23Granulocyte Colony-Stimulating Factor 22Dexamethasone 21Methylprednisolone 19Bortezomib 19Chlorambucil 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia, Lymphocytic, Chronic, B-Cell × Bupropion × Clear all
NCT03301207 2019-12-05

A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy

Janssen Research & Development, LLC

Phase 1 Completed
25 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡